Horizon Therapeutics publishes data from Mirror study of Krystexxa

Horizon Therapeutics announced the publication of the long-term data from the MIRROR randomized controlled clinical trial of KRYSTEXXA or pegloticase, injection with methotrexate, a commonly used immunomodulator, in ACR Open Rheumatology. “Publication of these 12-month data reinforces key findings shown at Month 6, including the durability of urate-lowering response, reduced infusion reactions and reduced immunogenicity of pegloticase when co-administered with methotrexate,” said Kenneth Saag, M.D., author and Director of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham. “Encouragingly, urate-lowering efficacy with the co-therapy approach was sustained over time with continued treatment in most patients. Further, the number of patients seeing complete resolution of at least one tophus markedly increased between Month 6 and Month 12 of treatment.” This analysis extends the MIRROR randomized controlled trial body of data through Month 12 of treatment, showing a largely sustained patient response rate and similar safety profile as the Month 6 findings: .